Latest Breaking News On - பாயஂட் ஆய்வகங்கள் - Page 2 : comparemela.com

Caplin Point Laboratories jumped 7.03% to Rs 560.60 after the company s consolidated net profit surged 39% to Rs 67.92 crore on 29.49% rise in revenue from operations to Rs 278.71 crore in Q4 FY21 over Q4 FY20. On a consolidated basis, EBITDA surged 29.6% to Rs 95.15 crore in Q4 FY21 as against Rs 73.44 crore in Q4 FY20. EBITDA margin improved to 33% in Q4 FY21 from 31.3% in Q4 FY20. The geographical breakup of sales were: Latin America at 87%; Africa at 5% and US at 8%. Given the continued focus on cash flow, receivables sustained at 95 days despite growth in sales. With focus on need to keep Inventory closer to customers, the current level of inventory is likely to continue at similar levels.

United statesCaplin point laboratoriesLatin americaPoint laboratoriesCapital marketஒன்றுபட்டது மாநிலங்களில்கேப்ளின் பாயஂட் ஆய்வகங்கள்லத்தீன் அமெரிக்காபாயஂட் ஆய்வகங்கள்மூலதனம் சந்தை